SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Trautwein C, Possienke M, Schlitt HJ, Boker KH, Horn R, Raab R, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000; 95: 23432351.
    Direct Link:
  • 2
    Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69: 321326.
  • 3
    Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S. Hepatic osteodystrophy: static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989; 96: 213221.
  • 4
    Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RF, LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257261.
  • 5
    Guichelaar MMJ, Hay JE, Clarke BE, Malinchoc M. Incidence and pretransplant risk factors for posttransplant fractures in patients with chronic cholestatic liver disease [abstract]. J Hepatol 2000; 31(suppl 2): 49.
  • 6
    McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AGR, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology 1991; 14(4 Pt 1): 613619.
  • 7
    Eastell R. Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296300.
  • 8
    Bagur A, Mautalen C, Findor J, Sorda J, Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int 1998; 63: 385390.
  • 9
    Leidig-Bruchner G, Hosch S, Dididou P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342347.
  • 10
    Rodina MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998; 104: 459469.
  • 11
    Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Immunosuppression and other posttransplant effects of bone metabolism. Liver Transpl 2004; 10: 638647.
  • 12
    Compston JE, Greer S, Skingle SJ, Stirling DM, Price C, Friend PJ, et al. Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol 1996; 25: 715718.
  • 13
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001; 12: 484492.
  • 14
    Crosbie OM, Freaney R, McKenna MJ, Curry MP, Hegarty JE. Predicting bone loss following orthotopic liver transplantation. Gut 1999; 44: 430434.
  • 15
    Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200206.
  • 16
    Dickson ER, Fleming CR, Ludwig J. Primary biliary cirrhosis. Prog Liver Dis 1979; 6: 487502.
  • 17
    Dickson ER, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. Hepatology 1984; 4(suppl): 33S35S.
  • 18
    Karnofsky DA, Ableman WH, Craver LF. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634656.
  • 19
    Kao PC, Heser DW. Simultaneous determination of 26-hydroxy and 1.25-dihydroxyvitamin D from a single sample of dual cartridge extraction. Clin Chem 1984; 30: 5661.
  • 20
    Woodhead JS. The measurement of circulating parathyroid hormone. Clin Biochem 1990; 23: 1721.
  • 21
    World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1994; 843: 1129.
  • 22
    SAS Institute. SAS User's Guide, Vol. 1. Cary, NC: SAS Institute, 1989.
  • 23
    Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001; 34: 292298.
  • 24
    Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316323.
  • 25
    Guanabens N, Pares A, Ros I, Cabelleria L, Pons F, Vidal S, et al, Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatology 2005; 42: 573577.
  • 26
    Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998; 29: 729735.
  • 27
    Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 25812586.
  • 28
    Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14: 819827.
  • 29
    Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996; 31: 669678.
  • 30
    Shiomi S, Kuroki T, Masaki K, Takeda T, Nishiguchi T, Nakajiama S, et al. Osteopenia in primary biliary cirrhosis and cirrhosis of the liver in women, evaluated by dual-energy X-ray absorptiometry. J Gastroenterol 1994; 29: 605609.
  • 31
    Diamond T, Stiel D, Mason R, Lissner D, Bikkle D, Wilson S, Posen S. Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. J Clin Endocrinol Metab 1989; 69: 12341239.
  • 32
    Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewoon L, Evrovski J, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118: 145151.
  • 33
    Pares A, Guanabens N, Alvarez L, De Osaba MJ, Oriola J, Pons F, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001; 33: 554560.
  • 34
    Guardiola J, Xiol X, Sallie R, Nolla JM, Roig-Escufet D, Jaurrieta E, et al. Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation. Ann Intern Med 1999; 131: 752755.
  • 35
    Bevier WC, Wiswell RA, Pyka G, Kozak KC, Newhall KM, Marcus R. Relationship of body composition, muscle strength, and aerobic capacity to bone mineral density in older men and women. J Bone Miner Res 1989; 4: 421430.
  • 36
    Khosla S, Atkinson EJ, Riggs BL, Melton LJ. Relationship between body composition and bone mass in women. J Bone Miner Res 1996; 11: 857863.
  • 37
    Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res 2002; 17: 15631569.
  • 38
    Ormarsdottir S, Ljunggren O, Mallmin H, Olofsson H, Blum WF, Loof L. Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol 2001; 16: 14091414.
  • 39
    Munoz MT, Argente J. Anorexia nervosa: hypogonadotrophic hypogonadism and bone mineral density. Horm Res 2002; 57: 5762
  • 40
    Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP, et al. Bone loss at the femoral neck in premenopausal white women: effects of weight change and sex-hormone levels. J Clin Endocrinol Metab 2002; 87: 15391543.
  • 41
    Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88: 31673176.
  • 42
    Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 50815088.
  • 43
    Guichelaar MMJ, Malinchoc M, Sibonga JD, Clarke BL, Hay JE. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res 2003; 18: 21902199.
  • 44
    Porayko MK, Wiesner RH, Hay JE, Krom RA, Dickson ER, Beaver S, Schwerman L. Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991; 23: 14621465.
  • 45
    Bjoro K, Brandsaeter B, Wiencke K, Godang K, Bollerslev J, Schrumpf. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol 2003; 38: 320327.
  • 46
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, De Osaba MJ, et al. Bone mass and mineral metabolism in liver transplant recipients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68: 8386.
  • 47
    Floreani A, Fries W, Luisetto G, Burra P, Fagiuoli S, Boccagni P, et al. Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl 1998; 4: 311319.
  • 48
    Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl 1999; 5: 407413.
  • 49
    Hamburg SM, Piers DA, Berg van den AP, Slooff MJH, Haagsma EB. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11: 600606.
  • 50
    Gerstenfeld LC, Zurakowski D, Schaffer JL, Nichols DP, Toma CD, Broess M, et al. Variable hormone responsiveness of osteoblast populations isolated at different stages of embryogenesis of osteoblast populations isolated at different stages of embryogenesis and its relationship to the osteogenic lineage. Endocrinology 1996; 137: 39573968.
  • 51
    Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002; 36: 895903.